NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Aldesleukin (Primary) ; Dendritic cell vaccines (Primary) ; Fludarabine (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2016 Planned initiation date changed from 1 Jun 2016 to 1 Jun 2017.